FDA fast-tracks new Gleevec use

Earlier this week, Novartis got FDA priority review for Gleevec, its cancer med, for treatment of gastrointestinal stromal tumors after surgery. The agency will say "yea" or "nay" on the new indication within six months, rather than the typical 10. According to Novartis research, Gleevec cut the risk of tumors returning after surgery by 89 percent. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.